Hogan Lovells advises Jazz Pharmaceuticals

Hogan Lovells advised the biopharmaceuticals group Jazz Pharmaceuticals in relation to the acquisition by one of its subsidiaries of Alizé Pharma II, a subsidiary of the Alizé Pharma Group.

The cost of the transaction is estimated at EUR 18 million including EUR 8 million as an initial payment and supplementary payments of a total amount of EUR 10 million, subject to regulatory milestones being met.

The Hogan Lovells team advising Jazz pharmaceuticals was led in Paris by Jean-Marc Franceschi (Partner) assisted by Mathieu Frick and Andrea Segura (Associates) for corporate aspects and by Mikael Salmela (Partner) for regulatory aspects and commercial contracts.

Jones Day advised Alizé Pharma, a group operating in the biotechnology sector.

PRESS CONTACT

Eléonore Fleury

+33 1 53 67 18 41

eleonore.fleury@hoganlovells.com


Share Back To Listing

Loading data